✕
Login
Register
Back to News
Chardan Capital Maintains Buy on Senti Biosciences, Lowers Price Target to $11
Benzinga Newsdesk
www.benzinga.com
Neutral 47.4%
Neg 0%
Neu 47.4%
Pos 0%
Comments
No comments yet. Be the first!
Join the discussion
Login to comment
Login to comment